Purpose: The aim of this study was to identify the most appropriate measure of quality of life (QoL) for patients living with and beyond cancer. Methods: One hundred eighty-two people attending cancer clinics in Central London at various stages post-treatment, completed a series of QoL measures: FACT-G, EORTC QLQ-C30 , IOCv2 (positive and negative subscales) and WEMWBS, a wellbeing measure. These measures were chosen as the commonest measures used in previous research. Correlation tests were used to assess the association between scales. Participants were also asked about pertinence and ease of completion. Results: There was a significant positive correlation between the four domain scores of the two health-related QoL measures (.32 ≤ r ≤.72, P <.001), and a significant large negative correlation between these and the negative IOCv2 subscale scores (−.39 ≤ r ≤ −.63, P <.001). There was a significant moderate positive correlation between positive IOCv2 subscale and WEMWBS scores (r =.35, P <.001). However, neither the FACT-G nor the EORTC showed any significant correlation with the positive IOCv2 subscale. Participants rated all measures similarly with regards to pertinence and ease of use. Conclusion: There was little to choose between FACT-G, EORTC, and the negative IOC scales, any of which may be used to measure QoL. However, the two IOCv2 subscales capture unique aspects of QoL compared to the other measures. The IOCv2 can be used to identify those cancer survivors who would benefit from interventions to improve their QoL and to target specific needs thereby providing more holistic and personalised care beyond cancer treatment.
Bibliographical noteFunding Information:
This article presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Reference Number RP-DG-1212-10014). The views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health.
The SURECAN Development Grant investigators include in alphabetic order: Professor Kamaldeep Bhui (QMUL), Professor Liam Bourke (Sheffield Hallam University), Professor Trudie Chalder (King?s College London), Professor Sandra Eldridge (QMUL), Professor John Gribben (QMUL), Professor Louise Jones (UCL), Professor Paul McCrone (King?s College London), Dr. Adrienne Morgan (QMUL), Professor Damien Ridge (University of Westminster), Dr. Rebecca Roylance (UCLH), Professor Steph Taylor (QMUL), Mr. Mohamed Thaha (QMUL). N/A
© 2021, The Author(s).
- Quality of life